Table 1.
Characteristics of MGUS Patients With SARS-CoV-2 Infection and COVID-19 Outcome Before and After anti-SARS-CoV-2 Vaccination
| Prevaccinationa | Postvaccination | P value | |
|---|---|---|---|
| Total number of pts | 91 | 86 | – |
| Mean age, y ± SD (range) | 65.6 ± 13.3 (29-89) | 65.9 ± 13.4 (31-90) | 0.84 |
| Gender (male/female) | 42/49 | 53/33 | 0.05 |
| Comorbidities, n (%)b | |||
| 0 | 29 (31.9) | 30 (34.9) | 0.67 |
| 1 | 30 (32.9) | 32 (37.2) | 0.55 |
| 2 | 19 (20.9) | 10 (11.6) | 0.09 |
| ≥3 | 13 (14.3) | 14 (16.3) | 0.71 |
| Mean number, n ± SD (range) | 1.3 ± 1.3 (0–5) | 1.035 ± 1.068 (0–3) | 0.29 |
| MGUS subtype, n (%) | (available in 86 patients) | ||
| IgG | 63 (73.2) | 64 (74.4) | 0.86 |
| IgA | 5 (6.0) | 6 (7.0) | 1.0 |
| IgM | 9 (10.4) | 14 (16.3) | 0.26 |
| Biclonal | 8 (9.3) | 2 (2.3) | 0.09 |
| LC only | 1 (1.1) | 0 | 1.0 |
| MGUS risk,c n (%) | (available in 47 patients) | ||
| 0 Low | 22 (46.8) | 54 (62.8) | 0.07 |
| 1 Low-intermediate | 22 (46.8) | 29 (33.7) | 0.13 |
| 2 High-intermediate | 3 (6.4) | 3 (3.5) | 0.44 |
| Total SARS-CoV-2-positive MGUS, n (%) | 91/1454 (6.2) | 86/1060 (8.1) | 0.07 |
| COVID-19 outcome | |||
| Presence of symptoms, n (%) | 54 (59.3) | 23 (26.7) | < 0.001 |
| Hospitalization, n (%) | 19 (20.9) | 2 (2.3) | < 0.001 |
| Hospitalization in ICU, n (%) | 10 (11.0) | 1 (1.2) | 0.009 |
| Death due to COVID-19, n (%) | 8 (8.8) | 1 (1.2) | 0.03 |
| Mean number of days from the last vaccine dose to SARS-CoV-2 infection, ± SD (range) | NA | 103 ± 80.3 (2-285) | NA |
a
Data extracted by Sgherza et al.9
b
Comorbidities evaluated included cardiovascular disease, pulmonary disease, diabetes, and nonhematological cancers.
c
Rajkumar SV et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106(3):812–817.
ICU = intensive care unit; MGUS = monoclonal gammopathies of undetermined significance; NA = not applicable; pts = patients; SD = standard deviation.